CA3010771A1 - Combination therapy with an iron compound and a citrate compound - Google Patents

Combination therapy with an iron compound and a citrate compound Download PDF

Info

Publication number
CA3010771A1
CA3010771A1 CA3010771A CA3010771A CA3010771A1 CA 3010771 A1 CA3010771 A1 CA 3010771A1 CA 3010771 A CA3010771 A CA 3010771A CA 3010771 A CA3010771 A CA 3010771A CA 3010771 A1 CA3010771 A1 CA 3010771A1
Authority
CA
Canada
Prior art keywords
compound
iron
combination therapy
citrate
sfp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3010771A
Other languages
French (fr)
Inventor
Ajay Gupta
Gary BRITTENHAM
Raymond Pratt
Vivian H. Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockwell Medical Inc
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of CA3010771A1 publication Critical patent/CA3010771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Combination therapy comprising an iron compound, preferably soluble ferric pyrophosphate (SFP), in combination with a citrate compound is disclosed. Methods of using the combination therapy in the treatment of iron deficiency, with or without anemia, including iron-refractory iron deficiency anemia and other iron-sequestration syndromes, and pharmaceutical compositions and kits comprising SFP or another iron compound and a citrate compound are also disclosed.
CA3010771A 2016-01-06 2017-01-05 Combination therapy with an iron compound and a citrate compound Abandoned CA3010771A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662275487P 2016-01-06 2016-01-06
US62/275,487 2016-01-06
US201662432564P 2016-12-09 2016-12-09
US62/432,564 2016-12-09
PCT/US2017/012300 WO2017120311A1 (en) 2016-01-06 2017-01-05 Composition therapy with an iron compound and a citrate compound

Publications (1)

Publication Number Publication Date
CA3010771A1 true CA3010771A1 (en) 2017-07-13

Family

ID=57963442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010771A Abandoned CA3010771A1 (en) 2016-01-06 2017-01-05 Combination therapy with an iron compound and a citrate compound

Country Status (5)

Country Link
EP (1) EP3399970A1 (en)
JP (1) JP2019501184A (en)
CN (1) CN108883085A (en)
CA (1) CA3010771A1 (en)
WO (1) WO2017120311A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135155A1 (en) * 2018-01-02 2019-07-11 Kashiv Pharma Llc A stable oral pharmaceutical composition of ferric citrate
CN112457350A (en) * 2020-11-30 2021-03-09 中国大冢制药有限公司 Ferric pyrophosphate citrate complex and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
JP4655338B2 (en) * 2000-07-06 2011-03-23 大正製薬株式会社 Drugs for improving iron deficiency anemia
US7857977B2 (en) 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
US7816404B2 (en) 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
IN2014DN08761A (en) * 2012-05-08 2015-05-22 Dsm Ip Assets Bv
EP2842434A1 (en) * 2013-08-28 2015-03-04 DSM IP Assets B.V. Iron supplementation of a bouillon concentrate

Also Published As

Publication number Publication date
JP2019501184A (en) 2019-01-17
WO2017120311A1 (en) 2017-07-13
EP3399970A1 (en) 2018-11-14
CN108883085A (en) 2018-11-23

Similar Documents

Publication Publication Date Title
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2018067512A8 (en) Spirocyclic compounds
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
WO2018187331A8 (en) Macrocyclic compound and uses thereof
WO2017027359A8 (en) Pyridines and their use in the treatment of cancer
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
WO2019099646A8 (en) Macrocyclic compounds and uses thereof
MX2020000135A (en) New quinolinone compounds.
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2016130581A8 (en) Combination cancer therapy
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
PH12020500079A1 (en) Novel substituted xanthine derivates
CA3010771A1 (en) Combination therapy with an iron compound and a citrate compound
MX2018007830A (en) Oral care compositions.
WO2019078698A3 (en) Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831